Human papillomavirus, or HPV, is the most common sexually transmitted infection in the United States, affecting between 60 and 80 percent of sexually active adults. Despite its prevalence, there is no cure. A study at The University of Texas Health Science Center (UTHealth) Medical School at Houston, however, could provide hope for people with HPV. It comes in the form of a pill containing an extract derived from an unusual source: mushrooms.
The extract, Active Hexose Correlated Compound (AHCC), comes from shiitake mushrooms and is a readily available nutritional supplement. It has been used to relieve side effects of chemotherapy, which is what originally interested Judith A. Smith, Pharm.D., associate professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at UTHealth Medical School. Smith began studying AHCC a decade ago.
“From a pharmacology perspective, I wanted to rule out any potential drug interactions with chemotherapy,” said Smith. “We then observed some antitumor effects and started digging deeper and learning more about its immune modulating effects.”
Smith and her team spent two years completing in vitro studies showing the effects of AHCC on HPV, largely because they were so taken aback by the results.
“We had a lot of healthy skeptics, and I’ve probably been the biggest of those skeptics. How could this nutritional supplement possibly eradicate one of the most difficult viruses we’ve been challenged with in the cancer arena?” said Smith.
There is no known cure for HPV, and strains of the virus also cause cancer, including cervical cancer, the second most common in women. Without a cure, women infected with HPV are left to wait and see if they develop cancer.
“If they’re tested and we tell them they’re positive, right now there’s nothing we can do. We say, ‘We’ll check you in another year,’” said Smith. “When HPV testing became approved and recommended, I thought, ‘Wow, how frustrating for women.’ It creates a lot of anxiety and feelings of lack of control.”
“We had a lot of healthy skeptics, and I’ve probably been the biggest of those skeptics. How could this nutritional supplement eradicate one of the most difficult viruses we’ve been challenged with in the cancer arena?” — Judith A. Smith, Pharm. D., associate professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at The University of Texas Health Science Center (UTHealth) Medical School at Houston
Vaccines against HPV are available, but the low vaccination rate and the number of people beyond the age of vaccination mean vast numbers of women are infected and left in limbo.
The lack of options inspired Smith to begin researching HPV a decade ago. Despite the success of the in vitro studies, however, she and her team were not convinced of the possible positive effects of AHCC on HPV.
“We did mouse studies and, again, repeated the mouse studies in two models,” said Smith. “We were able to treat with AHCC and eradicate the HPV, then stop treatment and see a durable response.”
That response was key to determining whether AHCC could be truly effective in treating HPV—it wouldn’t just suppress the virus, but eradicate it. Data from a third animal study enabled Smith and her team to tackle the next hurdle: testing the efficacy of AHCC in human patients. Thanks to philanthropic funds, they were able to complete a pilot study treating ten women with the nutritional supplement.
Each of the women in the pilot study was over 30 and had HPV positive persistent infections, meaning they had been infected for 18 months or more. None of the women had cancerous lesions. A main objective of the pilot study was to determine dosage and length of treatment.
Three patients showed complete eradication after stopping AHCC. Two have yet to complete their courses of AHCC, but have tested HPV negative. The remaining patients stopped taking AHCC before testing completely negative. The next step would be a Phase II double-blinded, placebo-controlled trial to confirm the early results of the pilot study.
The regimen they determined involves taking three grams of AHCC on an empty stomach once a day for up to five months. It’s a course of treatment Smith gladly shares.
“It’s definitely in the category of ‘it won’t hurt you,’” said Smith. “Will it definitely help you? I can’t tell you that. I’m not in any position, nor do we have the data, to say yes. We’re not there yet, but we’re trying to get there.”
The success of AHCC so far has been a happy surprise. “We had been looking at this the whole time going, ‘If this works, the potential is huge,’” said Smith. “And now ten years later, the potential could be more than I envisioned.”
Should AHCC studies continue to bring positive results, Smith’s vision is to make the treatment available to as many women as possible, eliminating that limbo between HPV infection and possible cancer diagnosis.
“If further studies confirm our early findings, my ultimate goal would be to be able to find the financial means to support bringing this to underserved patients throughout the world, and here in Texas. That’s where the HPV virus in women with no access to health care is kind of a perfect storm as to why people end up with cancer,” said Smith. “I really want to help those patients.”
Baylor College of Medicine will be closed Monday, May 28 in observance of Memorial Day. https://t.co/6CNQMhyJ92
Baylor College of MedicineBaylorCollegeOfMedicine
Baylor College of Medicine will be closed Monday, May 28 in observance of Memorial Day.
TAMU Health Sciences@TAMHSC
#TAMHSC researchers are working to solve #diabetes-related blindness: https://t.co/D1Pi8CaD0H #Health
#Melanoma survivor explains how #immunotherapy #clinicaltrial and @DrSapnaPatel gave her hope. #CancerMoonShot #endcancer https://t.co/gxr9MaYsHi
MD Anderson Cancer CenterMDAnderson
Leticia Rousseve found comfort whenever she verbalized her frustrations and feelings to others who understood what she was going through as a caregiver for her husband, James, during his soft tissue sarcoma treatment. “This taught me an important lesson that I now share with others going through cancer: you are not alone.” Now, she pays it forward by volunteering with myCancerConnection, MD Anderson’s one-on-one cancer support community of patients, survivors and caregivers who have been there. #endcancer
At sprawling VA hospital in southern Dallas, a righteous battle to keep the promise to care for America's Veterans https://t.co/yBX7Jqyn6X via @dallasnews
6.1, 11:30 a.m.-1 p.m.: Join @MethodistHosp Cancer Center at St. John for a celebration and luncheon as we honor those living with a history of cancer. Register today: https://t.co/epZbgu9fA0 https://t.co/FLv19JSQs0
Today’s #VeteranOfTheDay is @USArmy Veteran M. Ross Kirk. https://t.co/Z1oqPWmWig
U.S. Department of Veterans AffairsVeteransAffairs
Today’s #VeteranOfTheDay is Army Veteran M. Ross Kirk. Ross served for 28 years and retired in 1988. He attained the rank of lieutenant colonel. Ross served two tours in Vietnam with the 4/39th Infantry Battalion, the 9th Infantry Division and the 5th Special Forces Group with the Chaplain Corps. He was also a member of the 101st Airborne Division, the 18th Airborne Corps 1st Division, and the Green Beret Parachute Demonstration Team. He wore the Green Beret on active duty for nine years and is nicknamed the “Leapin’ Deacon” due to his 225 military jumps, including 50 HALO (high altitude, low opening) jumps and 450 sport parachute jumps. Ross’ positions in the Army included Command Chaplain for the Special Operations Command (Airborne) and Senior Chaplain of the Combined Peacekeeping Forces in the liberation of Grenada. He retired at Fort Riley, Kansas in 1988 and has lived with his wife Judy in Wakefield, Kansas for 27 years. They have four children, eight grandchildren and one great-grandchild. Ross was awarded four Bronze Stars, five Air Medals, the Meritorious Service Medal with three Oak Leaf Clusters, the Joint Service Commendation Medal, the Army Commendation Medal with two Oak Leaf Clusters, the Army Achievement Medal and the Good Conduct Medal. He also earned the Ranger Tab, the Special Forces Tab and Master Parachutist and Air Assault Badges. Thank you for your service, Ross!
New @USDOT program provides free pilot training for Veterans https://t.co/z6mIJVPMlU via @Militarydotcom
New research funded by Department of Defense grants will look into why some women with estrogen receptor-positive breast cancer develop resistance to endocrine therapies. https://t.co/TMhNyXWZ8Y
Baylor College of MedicineBaylorCollegeOfMedicine
Congratulations to M.D/Ph.D. student Muhammad Saad Shamim on becoming a 2018 fellow of the Paul & Daisy Soros Fellowships for New Americans program.
#Chemobrain is real. Learn more about this common #cancer treatment side effect: https://t.co/86Kcj2AzFy #endcancer https://t.co/iH7IP2dIUv
What you need to know about #prostatecancer screening: https://t.co/Sbt5pA5B0J @oncolognews #endcancer
Dr. Elizabeth McIngvale talks about her journey with obsessive compulsive disorder. https://t.co/SxpIBc1gyA #MentalHealthAwarenessMonth